middle.news
Opthea Advances Sozinibercept Trials with $131.9M Cash Buffer and R&D Boost
10:43am on Friday 31st of January, 2025 AEDT
•
Biopharmaceutical
Read Story
Opthea Advances Sozinibercept Trials with $131.9M Cash Buffer and R&D Boost
10:43am on Friday 31st of January, 2025 AEDT
Key Points
Sozinibercept Phase 3 trials (COAST and ShORe) fully enrolled
Received US$10.4 million R&D tax incentive
Cash balance of US$131.9 million at December 31, 2024
Operational spend of US$46 million in Q2 FY25 advancing clinical trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Opthea (ASX:OPT)
OPEN ARTICLE